Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

张鑫,刘志红,郑敬民,陈朝红,陈强,牛建英,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298x.2003.05.013

2003-01-01

Abstract:Objective: Tacrolimus is an immunosuppressive drug with narrow therapeutic range and wide interindividual variation in its pharmacokinetics. P-glycoprotein(P-gp) and CYP3A play an important role in the absorption or metabolism of tacrolimus. The polymorphism 3435CT of MDR1, the gene encoding P-gp, could influence the expression and activity of P-gp, while it was proved that the activity of CYP3A5 was correlated with the CYP 3AP1 A-44G polymorphism. The aim of this study was to evaluate whether the MDR1 polymorphism or the CYP 3AP1 polymorphism were associated with tacrolimus concentration/dose ratio. Methodology: Forty one lupus nephritis or membranous nephropathy patients treated with tacrolimus were enrolled in this study. Their body weight, dosage and concentration of tacrolimus were observed. CYP 3AP1 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis. Results: According to CYP 3AP1 genotype, the concentration/dose ratio was higher in AA homozygotes than that in the patients with at least one G allele (151.3±93.4, n =21 vs 69.2±39.4, n =20, p 0.001). The difference between MDR1 CC and CT/TT subjects was also statistically significant (73.7±38.2, n =12 vs 126.8±91.3, n =29, p 0.05). Conclusion: CYP 3AP1 A-44G polymorphism and MDR1 C3435T polymorphism are associated with tacrolimus pharmacokinetics and dose requirements. Pharmacogenetic methods could be employed prospectively to help the dose selection and to individualize immunosuppressive therapy according to this information.